MB
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC : From Bedside to Bench and Back | BioDrugs |  | 2025 | 15 | 33 | ||
| Unveiling the landscape of uncommon EGFR mutations in NSCLC-A systematic review | Journal of thoracic oncology | | 2024 | 49 | 259 | ||
| Management of stage III non-small-cell lung cancer : rays of hope | Exploration of targeted anti-tumor therapy | | 2024 | 35 | 18 | ||
| Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC : A Brief Report | Journal of thoracic oncology | | 2024 | 4 | 1 | ||
| Bringing immune-checkpoint inhibitors earlier in the management of non-small cell lung cancer | Translational lung cancer research | | 2023 | 59 | 10 | ||
| The evolving role of immune-checkpoint inhibitors in malignant pleural mesothelioma | Journal of clinical medicine | | 2023 | 24 | 22 | ||
| Novel targets for immune-checkpoint inhibition in cancer | Cancer treatment reviews | | 2023 | 51 | 28 |
